Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study
Titel:
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study
Auteur:
Angevin, Eric Cassier, Philippe A. Italiano, Antoine Gonçalves, Anthony Gazzah, Anas Terret, Catherine Toulmonde, Maud Gravis, Gwenaëlle Varga, Andrea Parlavecchio, Cédric Paci, Angelo Poinsignon, Vianney Soria, Jean-Charles Drubay, Damien Hollebecque, Antoine